Intrinsic Alpha

Company Snapshot

Disc Medicine, Inc. investment report

Start with IRON at a glance, then work through valuation, price history, fundamentals, management, competitors, and analyst expectations.

Disc Medicine, Inc.

NASDAQ:IRON

Biotechnology

Healthcare
$76.11 -0.03%

-$0.02 today

Market cap
$2.92B
Beta
2.10
P/E (TTM)
-11.2
EPS (TTM)
-$6.28
52W Low $40.00High $99.50

Volume 0.65M

Average 0.47M

Intrinsic Value

IRON Intrinsic Value

Start with the valuation result. Compare the current market price with the system DCF estimate, then use the supporting sections below to decide whether the assumptions are reasonable.

Disc Medicine, Inc.

NASDAQ:IRON

Intrinsic Alpha fair value

Locked

Current Price

$76.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.

Monitor IRON

Get notified when the price moves into your range

Use alerts to turn the valuation into an action plan instead of checking the stock manually.

Price alerts

Get notified when IRON drops below your target

Current price baseline

$76.11

Current price

Current price $76.11

Selected target$60.89

Sign in to activate price alerts.

Price History

How has IRON traded over time?

Review how the market has priced Disc Medicine, Inc. over time, alongside earnings and dividend events, before deciding whether today’s price is unusual.

Price history

Dividend-adjusted closing price

Period change

-15.76%

Period high

$94.11

Period low

$55.74

Latest

$76.11

Investment Notes

Capture the investment case

Write down the key idea, risks, and what would change your mind before testing the thesis against the fundamentals below.

My notes

Journal entries for IRON

Sign in to keep notes

Keep your research and decisions in your personal journal.

Sign in / Sign up

Fundamental Analysis

Test company quality against your thesis

Work through profitability, revenue mix, financial position, cash generation, compounding numbers, and growth to see whether the business supports the investment case.

Earnings Quality

Follow revenue through to net income

Use the waterfall to see which costs, margins, and operating lines explain how much of each sales dollar becomes profit.

IRON Earnings Waterfall · TTM

NASDAQ:IRON · Revenue to Net Income

Key Ratios

EPS$-6.36
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-11.1
P/S Ratio0.0

Analysis

$0 of revenue converted into -$243.1M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-6.36, tying the income statement back to per-share earnings.

Revenue Mix

See which products and regions drive the business

Growth is easier to trust when you know where it comes from. Check whether one segment or region carries the company and how the mix is shifting.

Revenue by segment

Where IRON earns its revenue, as reported in company filings

This company does not report revenue segments.

Financial Position

Check what supports the company underneath the income statement

The balance sheet shows liquidity, debt, asset mix, and book value quality before you rely on earnings or growth assumptions.

Balance Sheet

Assets, liabilities & equity

Cash & Equivalents$90.0M
Short-term Investments$592.8M
Other Current$14.6M
Total Current Assets$697.4M
PP&E (Net)$1.6M
Other Non-current$496.0K
Total Non-current Assets$2.1M
Total Assets$699.5M

Analysis

Selected assets total $699.5M for Latest. The largest visible component is Short-term Investments at $592.8M, about 84.8% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.

Cash Generation

Test whether profit turns into cash

Free cash flow connects accounting earnings to owner earnings, showing how much cash remains after reinvestment needs.

Free Cash Flow

Net Income to FCF bridge

Cash Flow Statement

FY2025

= Net Income-$212.2M
+ D&A$281.0K
+ Stock-Based Comp$34.3M
+ Deferred Tax$0
+ Working Capital$3.5M
- Other Non-Cash-$6.4M
= Operating Cash Flow-$180.4M
- Capex-$933.0K
= Free Cash Flow-$181.3M

Analysis

FY2025 free cash flow is -$181.3M. FCF conversion is 85.5% of net income. Operating cash flow was -$180.4M, with capex of -$933.0K. The largest bridge item is Stock-Based Comp at $34.3M.

Quality Snapshot

Check the numbers that compound value

Check whether earnings, revenue, equity, cash, and returns on capital are moving in the same direction as your written thesis.

Big Five Numbers

CAGR by period · ROIC shows average

Metric 10yr 5yr3yr1yr
EPS
N/AN/AN/AN/A
Revenue
N/AN/AN/AN/A
Equity
N/AN/A-50.2%+30.4%
Cash
N/AN/A-22.3%-52.6%
ROIC
N/A-29.5%-28.1%-30.6%

Analysis

Latest growth is strongest in Equity at +30.4% and weakest in Cash at -52.6%. Three-year average ROIC is -28.1%, which helps show whether that growth is being earned efficiently.

Growth Profile

Compare historical growth with forward expectations

Strong past growth matters more when analysts still expect the business to expand without relying on one temporary driver.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A4 analysts
RevenueN/AN/AN/A
N/A5 analysts
Net IncomeN/AN/AN/A
N/A5 analysts
EBITN/AN/AN/A
N/A5 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Management

Judge how Disc Medicine, Inc. allocates capital

Review returns on capital, owner payouts, dividend durability, insider activity, and the leadership responsible for these decisions.

Capital Efficiency

Returns on equity, invested capital, and assets help separate durable operators from businesses that only grow by adding more capital.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-28.7%

avg 23.5%

ROIC

-30.6%

avg -4322.6%

ROA

-26.3%

avg -103.7%

Analysis

ROA is currently the strongest return metric at -26.3% versus its period average of -103.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Dividend Record

A dividend is more useful when growth, payout ratio, and free cash flow support the current yield.

Dividends

Dividend history, growth & yield

Dividends

Yield

0.00%

Annual Div/Share

$0.00

Payout Ratio

0.0%

Frequency

—

Shareholder Yield

0.00%

Next Ex-Date

Not announced

Next Payment

—

Analysis

The current indicated dividend yield is 0.00%. The payout ratio is 0.0%, so compare payout growth against earnings coverage.

Owner Returns

Dividends, buybacks, and debt paydown show whether excess cash is being reinvested, returned, or used to strengthen the balance sheet.

Shareholder Returns

Dividend, buyback & debt paydown yields

Management

Dividend Yield (TTM)

0.00%

Buyback Yield (TTM)

0.00%

Debt Paydown (TTM)

0.00%

Total Yield (TTM)

0.00%

Showing limited history. Sign in for more

Analysis

Total TTM shareholder yield is 0.00% including 0.00% from debt paydown. The largest current contributor is dividends at 0.00%, which helps show whether capital returns are coming from direct cash payouts, share count reduction, or balance sheet cleanup.

Insider Activity

Insider transactions add context to ownership incentives and can reveal when leadership behavior diverges from the public investment case.

Insider Trading

SEC Form 4 transactions — last 12 months

Management

Buys

0

$0.00

Sells

96

$48.75M

Net Transaction Value

−$48.75M

Net selling

Most Active

Bitterman Kevin

47 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Nov 10, 26

Savage William Jacob

Direct

Sell$1.4M
Oct 21, 26

Bitterman Kevin

Indirect

Sell$21.3K
Oct 21, 26

Bitterman Kevin

Indirect

Sell$1.1M
Oct 21, 26

Bitterman Kevin

Indirect

Sell$920.2K
Oct 20, 26

Bitterman Kevin

Indirect

Sell$229.4K
Oct 20, 26

Bitterman Kevin

Indirect

Sell$190.9K
Oct 20, 26

Bitterman Kevin

Indirect

Sell$4.4K
Oct 19, 26

Bitterman Kevin

Indirect

Sell$395.2K
Oct 19, 26

Bitterman Kevin

Indirect

Sell$9.2K
Oct 19, 26

Bitterman Kevin

Indirect

Sell$474.8K

1–10 of 96

Summary

Insiders reported 0 buys worth $0.00 and 96 sells worth $48.75M over the last 12 months. That adds up to net selling of $48.75M. Bitterman Kevin was the most active insider with 47 transactions.

Leadership

Leadership context helps you judge who is responsible for strategy, capital allocation, and execution.

Management

Key executives, compensation & ownership

View management
NameTitleCompensationAgeShares OwnedOwnership %

John D. Quisel

Chief Executive Officer, President & DirectorUSD 1.26M55150.12K0.39%

Jean Franchi

Chief Financial OfficerUSD 838.98K60——

William Jacob Savage

Chief Medical OfficerUSD 836.84K5263.45K0.17%

Pamela Stephenson

Chief Commercial OfficerUSD 832.1K5881.00K0.21%

Jonathan Yu

Chief Opearating OfficerUSD 811.56K45——

Donald William Nicholson

Executive ChairmanUSD 170K696.21K0.02%

Brian MacDonald

Founder & Chair of Scientific Advisory BoardUSD 88.54K65——

Rahul Rajan Kaushik

Chief Technical Officer————

Srikanth Venkatraman

Senior Vice President & Head of Chemistry————

Lisa Amaya Price

Chief Human Resources Officer————

Rahul Khara

Chief Legal Officer & Secretary—4449.80K0.13%

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 10, 2026.

Alternatives to IRON

Compare Disc Medicine, Inc. with similar companies

A stock can look attractive in isolation and still be less compelling than a peer. Check competitors before committing to the thesis.

Analysts

What Wall Street expects from IRON

Compare consensus price targets and ratings with your own valuation to understand how much optimism the market is already pricing in.

Analyst Targets

See where analysts expect IRON to trade next

Compare the latest consensus target range with the current share price to understand how much upside or downside Wall Street is pricing in.

Wall Street price targets

1-year price history with analyst consensus target

Growth

Unlock analyst target range

Sign in free to see low, average, high targets and implied upside for IRON.

Sign in free

Analyst Ratings

How analysts rate IRON today

See the buy, hold, and sell split behind the consensus and whether recent rating changes lean toward upgrades or downgrades.

Analyst ratings

Buy, hold, and sell recommendations and recent rating changes

Unlock analyst ratings

Sign in free to see the buy/hold/sell breakdown and recent rating changes for IRON.

Sign in free

Company Overview

Understand how Disc Medicine, Inc. makes money

Ground the financial evidence in the company profile, business description, and key facts.

Key Information

Filings
NameDisc Medicine, Inc.
TickerIRON
ExchangeNASDAQ Global Market
IPO DateAug 12, 2020
IndustryBiotechnology
SectorHealthcare
Market Cap$2.92B
Shares Out38.20M
LocationWatertown, MA, US

Stock Analysis

Turn the IRON report into your next decision

Record your conclusion, evidence, and concerns in a structured analysis workspace.

Investment analysis

Turn IRON research into a decision

Work through Know the Business, Test the Moat, Management, and Intrinsic Value in one private, repeatable checklist.

NASDAQ:IRON
Know the Business
Test the Moat
Management
Intrinsic Value

Sign in on the next page to save a private analysis.

Start analysis

FAQ

Common questions about IRON

Resolve the remaining questions before moving into the detailed workspaces.

Explore

Continue your research

Open the detailed valuation, financial, health, and management workspaces.